Medical Information Services. 5.5.1 DISTRIBUTOR shall provide medical information services for the Product in the Territory through qualified personnel in accordance with this Agreement and as further detailed in this Section 5.5. Medical queries from the Territory received by the SUPPLIER shall be directed to DISTRIBUTOR´s Address for Medical Information Purposes as further detailed in ANNEX J.
Medical Information Services. On or before the Effective Date, MPL shall provide to Distributor, MPL's current database of Medical Information Letters regarding the Licensed Products; provided, however, that Distributor shall be solely responsible and liable for any use or modification of such Medical Information Letters by Distributor. MPL shall refer all requests and inquiries from healthcare professionals and consumers of the Licensed Products to Distributor, and Distributor will provide to MPL the telephone number to which such call will be referred. Distributor and MPL have jointly developed written procedures for the administration of and response to medical inquiries concerning the Licensed Products by consumers, physicians, pharmacists and other health care professionals, as set forth in EXHIBIT 6.05. Distributor and MPL shall each comply with the provisions thereof.
Medical Information Services. Wyeth shall remain responsible for responding to any and all medical inquiries received before the Closing Date. Wyeth shall satisfy these requirements within thirty (30) days after the Closing Date. From and after the Closing Date, Genzyme shall be solely responsible for all medical information support related to all medical inquiries received from and after the Closing Date, including but not limited to: provision of standard medical responses, custom creation of medical responses, maintaining a medical inquiry database which captures the nature of the inquiry and the response provided, literature review for relevant Synvisc-related publications and appropriate capture and forwarding of post-marketing adverse events and product complaints. In the event that Wyeth receives any medical inquiry or request related to Synvisc Product after the Closing Date, Wyeth shall promptly refer such inquiry to an individual designated by Genzyme. [**] = Portions of this exhibit have been omitted pursuant to a confidential treatment request. An unredacted version of this exhibit has been filed separately with the Commission.
Medical Information Services. On or before the Commencement Date, GSK will provide to Myogen, GSK's current database of Medical Information Letters regarding the Product; provided, however, that Myogen will be solely responsible and liable for any use or modification of such Medical Information Letters by Myogen. From and after the Commencement Date, GSK will refer all requests and inquiries from healthcare professionals and consumers of the Product to Myogen, and Myogen will provide to GSK the telephone number to which such call will be referred. Within thirty (30) days of the Effective Date, Myogen and GSK will jointly developed written procedures for the administration of and response to medical inquiries concerning Product by consumers, physicians, pharmacists and other health care professionals. Myogen and GSK will each comply with the provisions thereof.
Medical Information Services. DURA and BMS have jointly developed written procedures for the administration of and response to medical inquiries concerning the Products by consumers, physicians, pharmacists and other health care professionals, as set forth in EXHIBIT 6.2. DURA and BMS shall each comply with the provisions thereof.
Medical Information Services. On or within [***] after the Effective Date, Santarus will provide to GSK, Santarus’ current database of Medical Information Letters (if any) regarding the PR Product; provided, however, that GSK will be solely responsible and liable for any use or modification of such Medical Information Letters by GSK. From and after the Effective Date, at GSK’s cost and expense, Santarus will promptly refer all requests and inquiries from healthcare professionals and consumers of the PR Product in the Territory to GSK, and GSK will provide to Santarus the telephone number to which such call will be referred. Within thirty (30) days of the Effective Date and prior to launch, GSK and Santarus will jointly develop written procedures for the administration of, and response to, medical inquiries concerning PR Product in the Territory by consumers, physicians, pharmacists and other health care professionals. GSK and Santarus will each comply with the provisions thereof at GSK’s cost and expense.
